Table 3.
Prognostic Factors for Progression-Free Survival
| n | Hazard Ratio (95% CI) | P | |
|---|---|---|---|
| Sex, Male versus Female | 41 | 0.86 (0.39–1.90) | .71 |
| Type of Perioperative Chemotherapy | |||
| Adjuvant versus neoadjuvant | 41 | 0.65 (0.32–1.32) | .23 |
| GC versus others | 41 | 1.72 (0.86–3.43) | .13 |
| Number of Cycles of Perioperative Chemotherapy, Continuous | 41 | 1.04 (0.81–1.32) | .77 |
| Metastases at Recurrence, Visceral versus Nonvisceral | 41 | 1.55 (0.80–2.98) | .19 |
| Time From Last Perioperative Chemotherapy to First-Line Chemotherapy | |||
| ≥52 Weeks versus <52 weeks | 41 | 0.66 (0.34–1.27) | .21 |
| ≥78 Weeks versus <78 weeks | 41 | 0.66 (0.34–1.27) | .21 |
| ≥104 Weeks versus <104 weeks | 41 | 0.57 (0.26–1.25) | .16 |
| Log-transformation | 41 | 0.83 (0.60–1.13) | .24 |
| Age, Years | 41 | 0.99 (0.94–1.03) | .54 |
| ECOG Performance Status, 1–2 versus 0 | 41 | 4.78 (1.95–11.74) | <.001 |
| Hemoglobin, Anemic (<LLN) versus Nonanemic | 40 | 2.00 (1.02–3.92) | .045 |
| Leukocyte Count, >ULN versus <ULN | 39 | 1.77 (0.83–3.74) | .14 |
| Creatinine Clearance, ≥60 versus <60 ml/minute | 39 | 1.05 (0.45–2.43) | .92 |
| Albumin per Unit | 34 | 0.84 (0.44–1.61) | .60 |
| Type of First-Line Chemotherapy, GC versus Other | 41 | 1.20 (0.62–2.33) | .59 |
| Dose of Cisplatin, ≥70 versus <70 mg/m2 per Cycle | 41 | 0.90 (0.27–2.96) | .86 |
| Multivariate Model | |||
| ECOG performance status, 1–2 versus 0 | 40 | 4.47 (1.83–10.93) | .001 |
| Hemoglobin, anemic versus nonanemic | 40 | 1.95 (0.99–3.84) | .053 |
Abbreviations: ECOG = Eastern Cooperative Oncology Group; GC = gemcitabine and cisplatin; LLN = lower limit of normal; ULN = upper limit of normal.